New Copaxone Formulation Approved

From NeurologyWire

FDA has approved Tevas supplemental new drug application (sNDA) for three-times-a-week Copaxone 40mg/mL. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily Copaxone 20 mg/mL will continue to be ava...

Login to read story

Wednesday, March 05, 2014

Show last days of articles

Alzheimer's Association Awards Largest Ever Research Grant (...

From NeurologyWire

The Alzheimer's Association has received its largest ever research grant $8 million over four years to support the Longitudinal Evaluation of Amyloi...Full story

Monday, March 03, 2014

March is Multiple Sclerosis Awareness Month

From NeurologyWire

The Multiple Sclerosis Association of America (MSAA) recognizes March as MS Awareness Month. MSAA urges everyone to help raise awareness of multiple ...Full story

Thursday, February 27, 2014

Parkinson's Biomarker Initiative Expands Study of Genetics

From NeurologyWire

The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Resear...Full story

Tuesday, February 25, 2014

nternational Stem Cell Corporation Completes Pre-IND Meeting...

From NeurologyWire

International Stem Cell Corporation, a biotechnology company developing novel stem cell-based therapies and biomedical products,has completed discussi...Full story

Epilepsy Book for Children Released

From NeurologyWire

In the fourth book in the Great Katie Kate series, The Great Katie Kate Explains Epilepsy, author M. Maitland DeLand, MD, takes readers on a medical a...Full story Kicks Off National Sleep Awareness Week by...

From NeurologyWire

National Sleep Awareness Week 2014 is being held March 2-9. This sleep focused week celebrates the amazing health benefits restful sleep can provide, ...Full story Unveils New Original Series, "Pain in Unique Work P...

From NeurologyWire has unveiled their newest series, "Pain in Unique Work Places." This series is original content developed by the experts at"This se...Full story

Monday, February 24, 2014

Restless Sleep Linked to Widespread Pain in Older Adults

From NeurologyWire

Waking up and not feeling rested isn't just annoying. Researchers say that "non-restorative sleep" is the biggest risk factor for the development of w...Full story

Adam Levine Continues Partnership with the "Own It" Campaign

From NeurologyWire

While Adam Levine is recognized as the lead singer of Maroon 5 and one of four coaches on NBC's The Voice, he is also known for encouraging adults to ...Full story

Thursday, February 20, 2014

MS Association Publishes Research Update

From NeurologyWire

The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publica...Full story

Tuesday, February 18, 2014

Tysabri Data Show Significant Reductions In Disease Activity...

From NeurologyWire

Tysabri (natalizumab) data published online in the Journal of Neurology, Neurosurgery, and Psychiatry confirmed its safety profile and demonstrated a ...Full story

Thursday, February 13, 2014

Love and the Restless - New Survey Shows Impact of RLS on Re...

From NeurologyWire

The Willis-Ekbom Disease (WED) Foundation released new survey data indicating that the impact of Restless Legs Syndrome, also known as Willis Ekbom Di...Full story

Monday, February 10, 2014

Crossing the Lines Between Parkinson's and Alzheimer's

From NeurologyWire

As research unveils overlap in the biology in addition to long-noted shared clinical symptoms of Parkinsons and Alzheimers diseases, three non-profi...Full story

Tuesday, February 04, 2014

CorTechs Labs Inc. expands NeuroQuant's US Market reach with...

From NeurologyWire

CorTechs Labs has announced the renewed and expanded partnership and distribution agreement with Invivo Corporation (subsidiary of Philips Healthcare)...Full story

Tecfidera Approved in the European Union as a First-Line Ora...

From NeurologyWire

Tecfidera (dimethyl fumarate) has been approved by the European Commission (EC) as a first-line oral treatment for people with relapsing-remitting mul...Full story